restor3d, Inc. has successfully completed its acquisition of Conformis, Inc. following approval by Conformis’ stockholders on August 31, 2023. Conformis’ common stock ceased trading on NASDAQ as of September 5, 2023. The CEO of restor3d, J. Kurt Jacobus, expressed enthusiasm for the merger, emphasizing their commitment to delivering personalized orthopedic solutions for various body parts, including shoulders, feet, ankles, spine, knees, and hips. This acquisition enhances their capabilities in 3D printing, biomechanics modeling, and AI-based design automation, offering innovative personalized device solutions.
restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased trading on the NASDAQ prior to the opening of the NASDAQ on September 5, 2023.
“We are extremely excited to complete this important transaction and look forward to leveraging our combined portfolio to deliver personalized orthopedic solutions for the whole human body,” said J. Kurt Jacobus, CEO of restor3d. “With the addition of Conformis to the organization, we see tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopedic landscape, including shoulder, foot & ankle, spine, and large joints such as knees and hips. We have mapped out a product roadmap that will deepen and extend our offerings across the body, providing surgeons and patients with the personalized device solutions they deserve.”
restor3d manufactures a full range of personalized orthopedic devices from patient-specific, to patient-matched, as well as a range of associated ancillary products. With existing expertise in 3D printing of osseointegrative biomedical materials, biomechanics modeling, artificial-intelligence-based planning and design automation tools, the addition of Conformis propels the scalable future of best-in-class personalized device solutions to present day.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace
